SCHEMBL4768003

SCHEMBL4768003

NCC(=O)NCCS(=O)(=O)N(Cc1cccc(Cl)c1Cl)c1ccc(C(=O)NCc2ccc(C(F)(F)F)nc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.45
DGAT2 Q96PD7 1/20 0.39
TRPM8 Q7Z2W7 2/20 0.39
NAMPT P43490 10/20 0.38
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAPT P10636 1/20 0.37
SCN3A Q9NY46 1/20 0.37
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4778478 0.96 GAA (0.43) GAADGAT2TRPM8NAMPTLMNA
SCHEMBL4775189 0.93 GAA (0.46) GAADGAT2TRPM8NAMPTLMNA
SCHEMBL4774824 0.92 GAA (0.48) GAADGAT2TRPM8NAMPTLMNA
SCHEMBL4776119 0.92 GAA (0.47) GAADGAT2TRPM8NAMPTLMNA
SCHEMBL4775154 0.91 GAA (0.45) GAADGAT2TRPM8NAMPTLMNA
SCHEMBL4776189 0.91 GAA (0.47) GAADGAT2TRPM8NAMPTLMNA
SCHEMBL4773091 0.90 GAA (0.46) GAADGAT2TRPM8NAMPTLMNA
SCHEMBL4771090 0.90 GAA (0.46) GAADGAT2TRPM8NAMPTLMNA
SCHEMBL4773041 0.88 GAA (0.47) GAADGAT2TRPM8NAMPTLMNA
SCHEMBL4772464 0.87 GAA (0.48) GAADGAT2TRPM8NAMPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 GAA 466/4885DGAT2 3173/4885TRPM8 3499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.